# Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

> **NCT06970145** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 57 (estimated)

## Conditions studied

- Craniopharyngiomas

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06970145
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2026-04-20
- **Final completion:** 2028-04-20
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970145, "Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06970145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*